Prat et al. recently reported that an empirical cut-off of more than 20% for PgR-positive tumor cells was statistically proven to be significant for predicting survival differences among 2257 luminal-type breast cancer patients defined by their molecular classification [18]. The gene discussed is PGR; the disease is breast cancer.